Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer. Metanalysis using updated data on individual patients from 52 randomized clinical trials.B.M.J., 311: 899–909, 1995.
BunnP.A., KellyK.: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer; review of the literature and future directions.Clin. Cancer Res.,1998. In press.
4.
RothJ.A., FossellaF., KamokiR.: A randomized trial comparing preoperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer.J. Natl. Cancer Inst.;86: 673–80, 1994.
5.
RosellR., Gomez-CodinaJ., CompsR.: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer.N. Engl. J. Med., 330: 153–8, 1994.
6.
PassH.I., PogrebniakH.W., SteinbergS.M.: Randomized trial of neoadjuvant therapy for lung cancer, interim analysis.Ann. Thor. Surg., 53: 992–8, 1992.
7.
GiacconeG., PostmusP., DebruyneC.: Final results of an EORTC phase III study of paclitaxel versus tenipo-side in combination with cisplatin in advanced NSCLC.Proc. Am. Soc. Clin. Oncol.,16: 460a (A1653), 1997.
8.
BonomiP., KimK., ChangA.: Phase III trial comparing etoposide (E) cisplatin (C) versus taxol (T) with cisplatin G-CSF (G) versus taxol-cisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group (ECOG) trial.Proc. Am. Soc. Clin. Oncol.,15: 382 (A1145), 1996.
9.
EvansW.K., WillB.P., BerthelotJ.M.: Estimating the cost of lung cancer diagnosis and treatment in Canada.The POHEM model. Can. J. Oncol., 5: 408–19, 1995.
10.
LaupacisA., FennyD., DetskyA.S.: How attractive does a new technology have to be to warrant adoption of the utilization? Tentative guidelines for using clinical and economic evaluation.Can. Med. Assoc. J., 146: 77–84, 1992.
11.
BonomiP.D., FinkelsteinD.M., RuckdeschelJ.C.: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the Eastern Cooperative Oncology Group.J. Clin. Oncol., 7: 1602–13, 1989.
12.
HuizingM.T., GiacconeG., Van WandermamL.J.C.: Pharmacokinetics of paclitaxal and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small cell lung cancer.J. Clin. Oncol., 1997;15: 317–29.
13.
ScagliottiG.V., CrinoL., PozziE.: Preliminary results of a dose-finding study of paclitaxel and carboplatin in patients with advanced non-small cell lung cancer.Semin. Oncol. 1996;23(suppl. 16): 80–83.
14.
TishlerR.B., SchiffP.B., GeardC.R., HallE.J.: Taxol: a novel radiation sensitizer.Int. J. Radiation Oncology Biol. Phys., 22: 613–7, 1992.
15.
LiebmannJ., CookJ.A., FisherJ.: In vitro studies of taxol as a radiation sensitizer in human tumor cells.J. National Can. Int., 86: 441–6, 1994.
16.
SafranH., KingT., ChoyT.: p-53 mutation do not predict response to paclitaxel/radiation for non-small cell lung carcinoma.Cancer, 78: 1203–9, 1996.
17.
EttingerD.S., FinkelsteinD.M., SarmaR.P.: Phase II study of paclitaxel in patients with extensive disease small cell lung cancer.J.C.O., 13: 1430–35, 1995.
18.
KirshciclingR.J., JungS.H., JettJ.R.per il North Central Cancer Treatment Group: A phase II trial of Taxol and G-CSF in previously untreated patients with extensive stage small cell lung cancer (SCLC).Proc. ASCO,13: 326, 1994.
19.
GlissonB.S., KurieJ.M., FoxN.J.: Phase I-II study of cisplatin, etoposide and paclitaxel in patients with extensive small cell lung cancer.Proc. ASCO,16: 1635, 1997.
20.
HainsworthJ.D., GrayJ.R., StroupS.I.: Paclitaxel, carboplatin and extended schedule etoposide in the treatment of small cell lung cancer.J.C.O., 15: 3464–70, 1997.
21.
GatzemeierU., ReckM., JagosU.: Chemotherapy of limited stage small cell lung cancer with carboplatin, paclitaxel and oral etoposide.8° International Congress on Anticancer Treatment. Paris, feb. 1998.
